Imiquimod: A review of basal cell carcinoma treatments

Journal of Drugs in Dermatology

Volumn 7, Issue 11, 2008, Pages 1044-1051

  Karve, Sudeep J ^a   Feldman, Steven R ^b   Yentzer, Brad A ^b   Pearce, Daniel J ^b   Balkrishnan, Rajesh ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOQUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT; IMIQUIMOD;

BASAL CELL CARCINOMA; CHEMOSURGERY; ECONOMICS; HUMAN; META ANALYSIS; PATHOLOGY; QUALITY OF LIFE; REVIEW; SKIN TUMOR; TUMOR RECURRENCE;

AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; HUMANS; MOHS SURGERY; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, BASAL CELL; QUALITY OF LIFE; SKIN NEOPLASMS;

EID: 58749111641     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Chen TM, Rosen T, Orengo I. Treatment of a large superficial basal cell carcinoma with 5% imiquimod: a case report and review of the literature. Dermatol Surg. 2002 April;28(4):344-346. (Pubitemid 34461431)
2. Lear W, Dahlke E, Murray CA. Basal cell carcinoma: review of epidemiology, pathogenesis, and associated risk factors. J Cutan Med Surg. 2007 January;11(1):19-30.
3. Tran H, Chen K, Shumack S. Epidemiology and aetiology of basal cell carcinoma. Br J Dermatol. 2003 November;149(Suppl 66):50-52. (Pubitemid 38064519)
4. How Many People Get Basal and Squamous Cell Skin Cancers? American Cancer Society, Inc 2007 July 18;Available at: URL: Last Accessed March 15, 2008: http://www.cancer.org/docroot/CRI/content/CRI-2-2-1X-How-many-people-get- nonmelanoma-skin-cancer-51.asp?rnav=cri.
5. Spencer JM, Tannenbaum A, Sloan L, Amonette RA. Does inflammation contribute to the eradication of basal cell carcinoma following curettage and electrodesiccation? Dermatol Surg. 1997 August;23(8):625-630.
6. Roewert-Huber J, Lange-Asschenfeldt B, Stockfleth E, Kerl H. Epidemiology and aetiology of basal cell carcinoma. Br J Dermatol. 2007 December;157(Suppl 2):47-51. (Pubitemid 350179630)
7. Drehs MM, Cook-Bolden F, Tanzi EL, Weinberg JM. Successful treatment of multiple superficial basal cell carcinomas with topical imiquimod: case report and review of the literature. Dermatol Surg. 2002 May;28(5):427-429. (Pubitemid 34596305)
8. Lee S, Selva D, Huilgol SC, et al. Pharmacological treatments for basal cell carcinoma. Drugs. 2007;67(6):915-934. (Pubitemid 46607391)
9. Aldara®. Graceway Pharmaceuticals, LLC, Bristol, TN 37620 2007 April;Available at: URL: Last Accessed March 15, 2008: http://www.aldara.com/ pdfs/aldara-ppi.pdf.
10. Geisse J, Caro I, Lindholm J, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004 May;50(5):722-733. (Pubitemid 38580549)
11. Geisse JK, Rich P, Pandya A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol. 2002 September; 47(3):390-398.
12. Peris K, Campione E, Micantonio T, et al. Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial. Dermatol Surg. 2005 March;31(3):318-323. (Pubitemid 43072987)
13. Schiessl C, Wolber C, Tauber M, et al. Treatment of all basal cell carcinoma variants including large and high-risk lesions with 5% imiquimod cream: histological and clinical changes, outcome, and follow-up. J Drugs Dermatol. 2007 May;6(5):507-513.
14. Tillman DK Jr, Carroll MT. Topical imiquimod therapy for basal and squamous cell carcinomas: a clinical experience. Cutis. 2007 March;79(3):241-248.
15. Vidal D, Matias-Guiu X, Alomar A. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma. Clin Exp Dermatol. 2004 September;29(5):518-525. (Pubitemid 39278200)
16. Berman B. Scientific rationale: combining imiquimod and surgical treatments for basal cell carcinomas. J Drugs Dermatol. 2008 January;7(Suppl 1):s3-s6.
17. Rigel DS, Torres AM, Ely H. Imiquimod 5% cream following curettage without electrodesiccation for basal cell carcinoma: preliminary report. J Drugs Dermatol. 2008 January;7(Suppl 1):s15-s16.
18. Tillman DK Jr, Carroll MT. A 36-month clinical experience of the effectiveness of curettage and imiquimod 5% cream in the treatment of basal cell carcinoma. J Drugs Dermatol. 2008 January;7(Suppl 1):s7-s14.
19. Beutner KR, Geisse JK, Helman D, et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol. 1999 December;41(6):1002-1007.
20. Schulze HJ, Cribier B, Requena L, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol. 2005 May;152(5):939-947. (Pubitemid 40704934)
21. Gollnick H, Barona CG, Frank RG, et al. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe. Eur J Dermatol. 2005 September;15(5):374-381. (Pubitemid 41337416)
22. Quirk C, Gebauer K, Owens M, Stampone P. Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks. Australas J Dermatol. 2006 November; 47(4):258-265. (Pubitemid 44536221)
23. Marks R, Gebauer K, Shumack S et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol. 2001 May;44(5):807-813. (Pubitemid 32391169)
24. Sterry W, Ruzicka T, Herrera E, et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol. 2002 December;147(6):1227-1236. (Pubitemid 36963032)
25. Vidal D, Matias-Guiu X, Alomar A. Fifty-five basal cell carcinomas treated with topical imiquimod: outcome at 5-year follow-up. Arch Dermatol. 2007 February;143(2):266-268. (Pubitemid 46294599)
26. Thissen MR, Kuijpers DI, Krekels GA. Local immune modulator (imiquimod 5% cream) as adjuvant treatment after incomplete Mohs micrographic surgery for large, mixed type basal cell carcinoma: a report of 3 cases. J Drugs Dermatol. 2006 May;5(5):461-464.
27. Ceilley RI, Del Rosso JQ. Current modalities and new advances in the treatment of basal cell carcinoma. Int J Dermatol. 2006 May;45(5):489-498.
28. Kumar P, Watson S, Brain AN, et al. Incomplete excision of basal cell carcinoma: a prospective multicentre audit. Br J Plast Surg. 2002 December;55(8):616-622. (Pubitemid 35469782)
29. Kumar P, Orton CI, McWilliam LJ, Watson S. Incidence of incomplete excision in surgically treated basal cell carcinoma: a retrospective clinical audit. Br J Plast Surg. 2000 October;53(7):563-566.
30. Spencer JM. Pilot study of imiquimod 5% cream as adjunctive therapy to curettage and electrodesiccation for nodular basal cell carcinoma. Dermatol Surg. 2006 January;32(1):63-69.
31. Tillman DK Jr, Carroll MT. Topical imiquimod therapy for basal and squamous cell carcinomas: a clinical experience. Cutis. 2007 March;79(3):241-248.
32. Wu JK, Oh C, Strutton G, Siller G. An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma. Australas J Dermatol. 2006 February;47(1):46-48.
33. Neville JA, Williford PM, Jorizzo JL. Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage. J Drugs Dermatol. 2007 September;6(9):910-914.
34. Tillman DK, Jr., Carroll MT. A 36-month clinical experience of the effectiveness of curettage and imiquimod 5% cream in the treatment of basal cell carcinoma. J Drugs Dermatol. 2008 January;7(Suppl 1):s7-s14.
35. Torres A, Niemeyer A, Berkes B, et al. 5% imiquimod cream and reflectance-mode confocal microscopy as adjunct modalities to Mohs micrographic surgery for treatment of basal cell carcinoma. Dermatol Surg. 2004 December;30(12 Pt 1):1462-1469. (Pubitemid 40053555)
36. Metcalf S, Crowson AN, Naylor M, et al. Imiquimod as an antiaging agent. J Am Acad Dermatol 2007 March;56(3):422-425. (Pubitemid 46273849)
37. Rodriguez-Vigil T, Vazquez-Lopez F, Perez-Oliva N. Recurrence rates of primary basal cell carcinoma in facial risk areas treated with curettage and electrodesiccation. J Am Acad Dermatol. 2007 January; 56(1):91-95. (Pubitemid 44969296)
38. Rowe DE, Carroll RJ, Day CL Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol. 1989 March;15(3):315-328. (Pubitemid 19085793)
39. Silverman MK, Kopf AW, Grin CM, Bart RS, Levenstein MJ. Recurrence rates of treated basal cell carcinomas. Part 2: Curettage- electrodesiccation. J Dermatol Surg Oncol. 1991 September; 17(9):720-726.
40. Silverman MK, Kopf AW, Bart RS, et al. Recurrence rates of treated basal cell carcinomas. Part 3: Surgical excision. J Dermatol Surg Oncol. 1992 June;18(6):471-476.
41. Werlinger KD, Upton G, Moore AY. Recurrence rates of primary nonmelanoma skin cancers treated by surgical excision compared to electrodesiccation- curettage in a private dermatological practice. Dermatol Surg. 2002 December;28(12):1138-1142. (Pubitemid 36076392)
42. Schmook T, Stockfleth E. Current treatment patterns in non-melanoma skin cancer across Europe. J Dermatolog Treat. 2003;14 (Suppl 3):3-10. (Pubitemid 37474596)
43. Vanaclocha F, Dauden E, Badia X, et al. Cost-effectiveness of treatment of superficial basal cell carcinoma: surgical excision vs. imiquimod 5% cream. Br J Dermatol. 2007 April;156(4):769-771. (Pubitemid 46452355)
44. Wagstaff AJ, Perry CM. Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions. Drugs. 2007;67(15):2187-2210. (Pubitemid 47557094)
45. De Cock E Nuijten MJ, Hollestein A, Hamel-Gariépy L. Cost-effectiveness model of Aldaratm (imiquimod) cream, 5% in superficial basal cell carcinoma in the Netherlands. Value in Health. 2005 November;8(6):A144.
46. Sverre JM, Kristensen FKO, Hamel-Gariépy L, Albrektsen T. Cost-effectiveness analysis: Aldaratm (imiquimod) cream, 5% in the treatment of superficial basal cell carcinoma in Norway. Value in Health. 2005 November;8(6):A143.
47. Leibovitch I, Huilgol SC, Selva D, et al. Basal cell carcinoma treated with Mohs surgery in Australia II. Outcome at 5-year follow-up. J Am Acad Dermatol. 2005 September;53(3):452-457. (Pubitemid 41195967)
48. Smeets NW, Kuijpers DI, Nelemans P, et al. Mohs' micrographic surgery for treatment of basal cell carcinoma of the face-results of a retrospective study and review of the literature. Br J Dermatol. 2004 July;151(1):141-147. (Pubitemid 39061291)
49. Boztepe G, Hohenleutner S, Landthaler M, Hohenleutner U. Munich method of micrographic surgery for basal cell carcinomas: 5-year recurrence rates with life-table analysis. Acta Derm Venereol. 2004;84(3):218-222. (Pubitemid 38649400)
50. Wennberg AM, Larko O, Stenquist B. Five-year results of Mohs' micrographic surgery for aggressive facial basal cell carcinoma in Sweden. Acta Derm Venereol. 1999 September;79(5):370-372. (Pubitemid 29414971)